Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects-Reference-Cited by-全球学者库

Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects

Published:2013-02-06 Issue:171 Volume:5 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Allen Joshua E.¹²³,Krigsfeld Gabriel³,Mayes Patrick A.³,Patel Luv³,Dicker David T.¹³,Patel Akshal S.¹⁴,Dolloff Nathan G.¹³,Messaris Evangelos⁵,Scata Kimberly A.¹³,Wang Wenge¹,Zhou Jun-Ying⁶,Wu Gen Sheng⁶,El-Deiry Wafik S.¹²³⁷

Affiliation:

1. Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medicine (Hematology/Oncology), Penn State Hershey Cancer Institute, Hershey, PA 17033, USA.

2. Biochemistry and Molecular Biophysics Graduate Group, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

3. Laboratory of Molecular Oncology and Cell Cycle Regulation, Departments of Medicine, Genetics, and Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

4. Department of Neurological Surgery, Penn State Hershey Medical Center, Hershey, PA 17033, USA.

5. Department of Surgery, Penn State College of Medicine, Hershey, PA 17033, USA.

6. Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA.

7. American Cancer Society, Atlanta, GA 30329, USA.

Abstract

TIC10 is a small molecule that activates Foxo3a through dual inactivation of Akt and ERK, up-regulates the expression of the TRAIL gene, an endogenous tumor suppressor, and effectively improves the therapeutic properties and utility of TRAIL as an anticancer therapy.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference44 articles.

1. The Receptor for the Cytotoxic Ligand TRAIL

2. An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL

3. KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene

4. Targeting death and decoy receptors of the tumour-necrosis factor superfamily

5. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural bioactive compounds and FOXO3a in cancer therapeutics: An update;Fitoterapia;2024-03

2. Significance of TRAIL/Apo-2 ligand and its death receptors in apoptosis and necroptosis signalling: Implications for cancer-targeted therapeutics;Biochemical Pharmacology;2024-02

3. TR-57 Treatment of SUM159 Cells Induces Mitochondrial Dysfunction without Affecting Membrane Potential;International Journal of Molecular Sciences;2024-01-18

4. Dermal FOXO3 activity in response to Wnt/β-catenin signaling is required for feather follicle development of goose embryos (Anser cygnoides);Poultry Science;2024-01

5. The adaptor protein 14-3-3zeta modulates intestinal immunity and aging in Drosophila;Journal of Biological Chemistry;2023-12